Highest-materiality recent filing
Oncotelic grants 17,796 RSUs to executives tied to exchange uplisting by June 2027
17,796 RSUs granted to directors, officers, employees, and advisors; each RSU convertible into 1,000 common shares via Series A Preferred.
Oncotelic completes merger transferring patent portfolio to Lunai for $20M Series B Preferred stock
Oncotelic contributed patent portfolio to Neurobridge Holdings, which merged into Lunai subsidiary; Oncotelic received 5 Series B shares (stated value $12.5M).
Oncotelic Therapeutics Reports FY 2025 Net Income of $249M Driven by JV Fair Value Gain
Net income attributable to Oncotelic was $249.3M in FY 2025, compared to net loss of $4.5M in FY 2024.
Oncotelic partners with TechForce Robotics to develop AI-enhanced GMP robotics platform
Joint development, manufacturing, and licensing agreement signed March 31, 2026.
Oncotelic raises $358.5K via secured convertible note with Mast Hill Fund
Issued $398,333.33 convertible promissory note (10% OID, 10% interest, 1-year maturity) to Mast Hill Fund for net proceeds of ~$350K after fees.
CEO Dr. Vuong Trieu receives 4,426 preferred shares (convertible to 4.426M common) for first milestone: converting $2.175M 2023 PPM Notes into 2025 Units.
Oncotelic completes Tranche 3 of unit offering, raising $1.1M from 22 investors
Issued 44 units under final Tranche 3; each unit includes a $25,000 principal, 12% 2-year convertible note.
Oncotelic closes initial $800K convertible note offering at 12% with warrants
Issued 32 units at $25,000 each to 21 accredited investors; total $800,000 raised.
Oncotelic closes initial 11 units of up to 500-unit offering with 12% notes and warrants
Initial closing of 11 units at $25,000 each in best-efforts offering of up to 500 units.
Engaged Jefferson Capital Ventures and Valor Nation for 18-month consulting and advisory services starting August 6, 2025.
Oncotelic secures $560K convertible note from Mast Hill; enters $25M equity purchase agreement
Issued $560,000 convertible promissory note to Mast Hill Fund, 10% OID, 10% interest, convertible at $0.07/share.
Oncotelic JV Sapu starts registrational Phase 2b/3 trial of OT-101 in pancreatic cancer
Sapu Bioscience (Oncotelic 45% JV partner) signed master services agreement with Cromos Pharma for OT-101 registrational trial.
Publication in Cancers shows high intra-tumor TGF-β2 level predicts poor survival in pediatric brainstem cancer (DIPG).
Oncotelic CMO Fatih Uckun resigns; CRO Seymour Fein assumes CMO role
Fatih Uckun, MD, PhD, resigned as Chief Medical Officer effective February 28, 2023.
Oncotelic details 2023 pipeline: 10+ OT-101 trials, pancreatic & glioma FPI, BARDA award
At least 10 investigator-initiated OT-101 trials planned in 2023 for NSCLC, pancreatic, melanoma, gliomas.
Oncotelic presents clinical data confirming TGF-β2 as target for gliomas; OS improvements shown
Reduced TGF-β2 increased OS from 9 to 22 mos in pediatric brainstem patients (N=95, p<0.0001).
55% of OT-101-treated pancreatic cancer patients had long-term disease control (21 of 37 pts).
Oncotelic issues $605K convertible note to Mast Hill; uses up to $250K to repay prior debt
Issued $605,000 convertible promissory note to Mast Hill Fund, LP at 12% interest, convertible at $0.10 per share.
Oncotelic contributed global, exclusive, perpetual, royalty-free license of OT-101 IP for 45% ownership in JV.
Oncotelic forms joint venture with Dragon Overseas; Dragon to invest $27.6M for 55% stake
Dragon Overseas invests $27.6M in cash and assets for 55% of JV; Oncotelic contributes OT-101 licenses for 45%.
Oncotelic issues $0.75M in convertible notes at $0.07/sh; repays $307.5K Geneva Notes
Issued three convertible notes on Dec 9, 12, 15, 2021 totaling $0.75M gross; part of a $1.25M financing round.
Oncotelic reports Q3 net loss of $1.9M; provides JV, license, and clinical updates
Net loss: $1.86M (($0.00)/share) vs $1.99M (($0.02)/share) in Q3 2020; operating expenses rose to $1.8M.
Oncotelic reports positive Phase 2 COVID-19 data: 3X survival benefit for critical patients
Safety endpoints met; OT-101 was safe in severe/critical COVID-19 patients.
On February 28, 2023, Fatih Uckun, MD, Ph. D, Chief Medical Officer (“ CMO ”) of Oncotelic Therapeutics, Inc. (the “ Company ”), notified the Company of his resignation as the Company’s CMO, effective February 28, 2023.
Dr. Seymour Fein MD, Chief Regulatory Officer (“CRO”) of the Company, will be taking over the CMO role.
On May 1, 2022, Oncotelic Therapeutics, Inc. (the “ Company ”) appointed Fatih Uckun, M.D., Ph.D. as its Consulting Chief Medical Officer for the Company.
In addition, on May 1, 2022, the Company appointed Dr. Seymour Fein as its Consulting Chief Regulatory Officer.
On July 16, 2021, David Diamond notified the Board of Directors (the “ Board ”) of Oncotelic Therapeutics, Inc. (the “ Company ”) of his decision to resign, effective immediately, from his position as a member of the Board.
On July 1, 2021, Chulho Park, Ph. D., provided notice to the Company of his intention to resign as the Chief Technology Officer of the Company, to be effective immediately.
Max materiality 0.90 · Median 0.55 · Most common event other_material